ASH 2024: Prospective study finds social and economic factors limit access to stem cell transplants for patients with AML
Many patients with acute myeloid leukemia (AML) can be cured by a transplant of blood-forming…
Browsing: ASH
ASH 2024: Study finds genetic changes, elevated leukaemia risk in ground zero first responders
First responders who worked at Ground Zero in the aftermath of the 2001 attacks on…
ASH 2024: Longer-term data for asciminib reinforce superior efficacy with favourable safety and tolerability profile in adults with newly diagnosed CML
Novartis today announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with asciminib…
ASH 2O24: Early signs of efficacy for a novel drug and a new predictive tool to guide patient care
Dana-Farber Cancer Institute researchers (USA) are breaking new ground in the fight against systemic mastocytosis,…
ASH 2023: Landscape for AML patients evolving rapidly as research discoveries advance new treatments
The treatment landscape for acute myeloid leukaemia (AML) is evolving rapidly, as research discoveries at Sylvester…
ASH 2023: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall…
ASH 2023: Study shows CAR-T cell therapy safe, effective even for high-risk patients
CAR-T cell therapy is a safe and effective treatment for diffuse large B-cell lymphoma (DLBCL),…
ASH 2023: Pilot study uses circulating tumour DNA to reliably predict relapse in patients with diffuse large B-cell lymphoma
Dana-Farber Cancer Institute investigators, in collaboration with researchers from the Broad Institute, demonstrated in a…
ASH 2023: Cell therapy appears safe and effective for lymphoma in remission
A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami…
ASH 2023: Patients with a common form of acute myeloid leukaemia report better quality of life when treatment includes new drug quizartinib
In a study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller…